CIAM
VERV

Caitong International Asset Management’s Verve Therapeutics VERV Stock Holding History

Caitong International Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-750
Closed -$8.42K – 2551
2025
Q2 		$8.42K Buy
750
+243
+48% +$1.39K 0.01% 789
2025
Q1 		$2.32K Buy
+507
New +$3.4K ﹤0.01% 1281

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Caitong International Asset Management's VERV Position: Q3 2025 in Review

Caitong International Asset Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 750 shares — an estimated $8.42K sold.

Caitong International Asset Management first reported a position in VERV in Q1 2025 and held it in 2 quarters. The position peaked at $8.42K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Caitong International Asset Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 750 Verve Therapeutics shares in Q3 2025, an estimated $8.42K.
  • Caitong International Asset Management first reported a position in Verve Therapeutics in Q1 2025 and held it in 2 quarters.
  • Caitong International Asset Management's Verve Therapeutics position peaked at $8.42K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Caitong International Asset Management's 13F filing for Q3 2025, filed 19 Nov 2025.